Park Square is excited to announce two placements at Rune Labs: Amy Gordon Franzen has been named Chief Executive Officer, and Adam Pellegrini has joined the Board of Directors. Rune Labs is a pioneering precision medicine company focused on neurology, supporting care delivery and therapy development using the most advanced AI and FDA-cleared algorithms. The company is backed by leading investors including Nexus NeuroTech, Eclipse Ventures, DigiTx, TruVenturo and Moment Ventures.

Amy joins Rune Labs from Tempus, where she played a foundational role in shaping the company’s trajectory from its formative stages into a leading precision-medicine platform used widely across healthcare. Most recently, as Senior Vice President and General Manager, she built and scaled a high-growth clinical trial organization by expanding its data assets and forging new provider and biopharma partnerships that accelerated enrollment across interventional and observational oncology trials. Before joining Tempus, she held leadership roles at Groupon, Nike, and McKinsey.

Adam is a recognized leader in AI-driven digital health, with more than two decades of experience building and scaling platforms that bridge technology, patients, and healthcare systems. His background spans leadership roles at Kaia Health, Jasper Health, CVS Health, Fitbit, and the American Cancer Society.

The appointment of these two seasoned healthcare leaders reflects Rune Labs’ robust foundation and long-term potential to advance the next generation of precision neurology.